Diabetes CKD Lifestyle Technology Study
Program to Improve Care in Complex Chronic Disease
調査の概要
詳細な説明
The purpose of this study is to develop and pilot test a lifestyle intervention in obese individuals with t2dm and concurrent stage 2-4 ckd. The counseling intervention will be based on social cognitive theory and supported by mobile (ipad) self-monitoring. Mobile self-monitoring is featured in the intervention to encourage vigilance to the diet in a manner that is not burdensome, enhance self-efficacy by integrating complex information regarding the ckd dietary regimen with a calorie-restricted diet, and permit real-time monitoring of weight, blood glucose, blood pressure, and self-reported diet and physical activity by the study team.
Specifically, the investigators will develop the methods for and pilot test the ckd lifestyle intervention in stage 2-4 ckd patients and explore the impact of the intervention on: (a) weight and fat mass, (b) blood pressure, (c) physical activity, (d) urinary sodium excretion, (e) serum phosphorus and calcium-phosphorus product, (f) kidney function as measured by serum cystatin-c, and (g) serum lipids. Additionally, we will evaluate the feasibility and acceptability of this intervention in terms of: (h) recruitment and retention, (i) time and cost associated with training ckd patients in technology-based self-monitoring and in delivering the intervention, (j) patterns of self-monitoring adherence over time, and (k) participant satisfaction with the intervention. Finally, we will describe: (l) the extent to which the intervention differentially adversely affects the nutritional health of participants as evidenced by low serum albumin or serum prealbumin; a body mass index (bmi) that falls below 20kg/m2; and subjective assessment of nutritional risk (e.g. Nausea, diarrhea, anorexia).
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
New York
-
New York、New York、アメリカ、10016
- NYU Langone Medical Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- In order to be eligible for the study, the individual must be 40 years of age or older; have a DRG Code of T2DM, GFR of 15-89 ml/min/1.73m2 and a BMI >30 kg/m2. The participant's physician of record will have verified that his/her patient can safely participant in an intervention study that involves weight loss and a goal of 150 minutes/week of moderate physical activity (comparable to brisk walking).
Exclusion Criteria:
Those with the following characteristics will be excluded by the investigators:
- unable or unwilling to provide informed consent; (2) unable to participate meaningfully in an intervention that involves group sessions (e.g., due to uncorrected hearing impairment, non-English-speaking); (3) unable to read or otherwise use an iPad to monitor dietary intake, physical activity, and weight (e.g., blind, illiterate); (4) unwilling to accept randomization assignment; (5) pregnant, or plans to become pregnant in the next 12 months, less than 3 months postpartum, or nursing or within 6 weeks of having completed nursing; (6) weight loss of > 10% in the past 6 months except for postpartum weight loss; and (7) individuals who are institutionalized (e.g., in a nursing home or personal care facility, or those who are incarcerated and have no control over their diet).
will exclude from the study those with underlying diseases which would increase the risk of participating in an intervention involving caloric restriction and physical activity. Such individuals would include those requiring treatment for cancer, exclusive of skin cancer other than melanoma, in the past 2 years; infectious diseases including untreated AIDS and active tuberculosis; uncontrolled hypertension of >190 mmHg SBP or >105 mmHg DBP despite treatment; stroke or TIA in the past 6 months; conditions requiring the use of home oxygen; or other chronic disease or condition likely to limit life span to < 1 year. A recent Institute of Medicine report suggests that reducing dietary sodium below 1,840 mg/day in those with mid- to late-stage heart failure may increase adverse events or mortality. Thus investigators will exclude those with heart failure.
Because of the dietary requirements of a pregnant woman, and the nature of weight loss and gain with pregnancy, inclusion of pregnant women in the study would confound the study results. Those who become pregnant during the study will be withdrawn from the study.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：防止
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ：Intervention: Lifestyle A.
Lifestyle A will receive an iPad loaded with a self-monitoring program used to support vigilance, reduce the information processing requirements, make readily available the information required to make good self-management decisions, provide real-time feedback, and permit targeted counseling in the context within which lifestyle behaviors occur. Using Social Cognitive Theory, the study dietitian will counsel participants via videoconferencing software on the iPad. Using the detailed nutritional and physical activity feedback from the self monitoring programs, the dietitian will use SCT to engage the participants in order to initiate healthy behavior change whilst reducing the demands of commuting for in person nutritional counseling. |
The intervention, which combines behavioral counseling with mobile self-monitoring, will be based on SCT which focuses on the role played by self-referent thought in the maintenance of behavior change.
Within SCT, behavior change and maintenance are influenced strongly by the individual's perceived self-efficacy.
他の名前：
|
|
他の：Intervention: Lifestyle B.
Participants randomized to this group will receive 6 months of routine care followed by a delayed intervention. Lifestyle B will employ the same diet and physical activity prescription as Lifestyle A as described above. Using Social Cognitive Theory, the study dietitian will counsel participants via videoconferencing software on the iPad. Using the detailed nutritional and physical activity feedback from the self monitoring programs, the dietitian will use SCT to engage the participants in order to initiate healthy behavior change whilst reducing the demands of commuting for in person nutritional counseling. |
The intervention, which combines behavioral counseling with mobile self-monitoring, will be based on SCT which focuses on the role played by self-referent thought in the maintenance of behavior change.
Within SCT, behavior change and maintenance are influenced strongly by the individual's perceived self-efficacy.
他の名前：
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Primary outcome: Weight. Weight will be obtained using a single, calibrated scale.
時間枠：Change from baseline in weight at 6 months
|
Change from baseline in weight at 6 months
|
|
|
Primary outcome: Urinary sodium. We will estimate dietary sodium intake from a spot urine sample.
時間枠：Change from baseline in Urinary sodium at 6 months
|
Change from baseline in Urinary sodium at 6 months
|
|
|
Primary outcome: Blood pressure. BP will be obtained using a mercury sphygmomanometer
時間枠：Change from baseline in Blood pressure at 6 months
|
Change from baseline in Blood pressure at 6 months
|
|
|
Primary outcome: Physical activity. Energy expenditures and minutes devoted to physical activity will be recorded using a FitBit.
時間枠：Change from baseline in Physical activity at 6 months
|
Change from baseline in Physical activity at 6 months
|
|
|
Primary outcome: Serum Cystatin-C. Cystatin-C is a serum protein that is used as a biomarker of kidney function
時間枠：Change from baseline in Cystatin-C at 6 months
|
Change from baseline in Cystatin-C at 6 months
|
|
|
Primary outcome: Lipoproteins. We will evaluate the impact of the intervention on serum lipids obtained after a 12-hour fast
時間枠：Change from baseline in Lipoproteins at 6 months
|
Change from baseline in Lipoproteins at 6 months
|
|
|
Primary outcome: Serum Phosphorus and corrected Calcium-Phosphorus product (CaxPO4) will be evaluated from a venipuncture sample.
時間枠：Change from baseline in Serum Phosphorus and corrected Calcium-Phosphorus product at 6 months
|
Corrected CaxPO4 is a measure of metastatic calcification, adjusted for the participant's nutritional status (serum albumin).
When serum albumin is < 4 g/dL, the algorithm for corrected CaxPO4 is [Ca + 0.8(4 - serum albumin)]x PO4.
When serum albumin if > 4 g/dL, corrected CaxPO4 = CaxPO4.
CaxPO4 is obtained with routine monthly labs on all HD patients
|
Change from baseline in Serum Phosphorus and corrected Calcium-Phosphorus product at 6 months
|
|
Primary outcome: Serum Phosphorus and corrected Calcium-Phosphorus product (CaxPO4) will be evaluated from a venipuncture sample.
時間枠：Change from baseline in Serum Phosphorus and corrected Calcium-Phosphorus product at 12 months
|
Corrected CaxPO4 is a measure of metastatic calcification, adjusted for the participant's nutritional status (serum albumin).
When serum albumin is < 4 g/dL, the algorithm for corrected CaxPO4 is [Ca + 0.8(4 - serum albumin)]x PO4.
When serum albumin if > 4 g/dL, corrected CaxPO4 = CaxPO4.
CaxPO4 is obtained with routine monthly labs on all HD patients
|
Change from baseline in Serum Phosphorus and corrected Calcium-Phosphorus product at 12 months
|
|
Primary outcome: Weight. Weight will be obtained using a single, calibrated scale.
時間枠：Change from baseline in weight at 12 months
|
Change from baseline in weight at 12 months
|
|
|
Primary outcome: Urinary sodium. We will estimate dietary sodium intake from a spot urine sample.
時間枠：Change from baseline in Urinary sodium at 12 months
|
Change from baseline in Urinary sodium at 12 months
|
|
|
Primary outcome: Blood pressure. BP will be obtained using a mercury sphygmomanometer
時間枠：Change from baseline in Blood pressure at 12 months
|
Change from baseline in Blood pressure at 12 months
|
|
|
Primary outcome: Physical activity. Energy expenditures and minutes devoted to physical activity will be recorded using a FitBit.
時間枠：Change from baseline in Physical activity at 12 months
|
Change from baseline in Physical activity at 12 months
|
|
|
Primary outcome: Serum Cystatin-C. Cystatin-C is a serum protein that is used as a biomarker of kidney function
時間枠：Change from baseline in Cystatin-C at 12 months
|
Change from baseline in Cystatin-C at 12 months
|
|
|
Primary outcome: Lipoproteins. We will evaluate the impact of the intervention on serum lipids obtained after a 12-hour fast
時間枠：Change from baseline in Lipoproteins at 12 months
|
Change from baseline in Lipoproteins at 12 months
|
協力者と研究者
スポンサー
捜査官
- 主任研究者：Mary Ann Sevick, ScD, RN、NYU School of Medicine
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。